Nuclear receptor PPARγ targets GPNMB to promote oligodendrocyte development and remyelination
-
By
-
Bing Han
-
Ming-Yue Bao
-
Qing-Qing Sun
-
Rui-Ning Wang
-
Xin Deng
-
Kun Xing
-
Feng-Lin Yu
-
Yan Zhang
-
Yue-Bo Li
-
Xiu-Qing Li
-
Na-Nan Chai
-
Gai-Xin Ma
-
Ya-Na Yang
-
Meng-Yuan Tian
-
Qian Zhang
-
Xing Li
-
Yuan Zhang
-
January 6, 2025
-
Clinical Scorecard: PPARγ Nuclear Receptor Regulates GPNMB to Enhance Oligodendrocyte Maturation and Remyelination
At a Glance
| Category | Detail |
|---|
| Condition | CNS demyelination and remyelination failure in neurological diseases |
| Key Mechanisms | PPARγ regulates OPC differentiation and myelin repair via targeting GPNMB |
| Target Population | Patients with CNS demyelinating diseases such as multiple sclerosis |
| Care Setting | Neurological and neurodegenerative disease management in clinical and research settings |
Key Highlights
- PPARγ expression increases during OPC differentiation and CNS myelination/remyelination.
- Pharmacological activation of PPARγ promotes OPC maturation and enhances remyelination in animal models.
- PPARγ directly targets GPNMB, a novel regulator driving OPC differentiation and myelinogenesis.
Guideline-Based Recommendations
Diagnosis
- Identify dysfunctional OPC accumulation in CNS demyelinated lesions.
- Assess PPARγ expression levels in oligodendrocyte lineage cells during disease progression.
Management
- Consider pharmacological activation of PPARγ using agonists such as pioglitazone or rosiglitazone to promote remyelination.
- Avoid attenuation of PPARγ function to prevent decreased OPC maturation and hindered myelin generation.
Monitoring & Follow-up
- Monitor OPC differentiation status and remyelination progress in CNS lesions.
- Evaluate therapeutic efficacy of PPARγ agonists in promoting myelin repair.
Risks
- Potential reduced therapeutic efficacy if PPARγ function is inhibited or knocked out in oligodendrocytes.
Patient & Prescribing Data
Patients with CNS demyelinating diseases, including multiple sclerosis
PPARγ agonists such as pioglitazone have shown to reduce demyelinating lesions and promote OPC differentiation and remyelination.
Clinical Best Practices
- Target PPARγ activation to enhance endogenous OPC differentiation and CNS remyelination.
- Utilize selective PPARγ agonists to improve myelin repair in demyelinating conditions.
- Investigate GPNMB as a downstream effector and potential therapeutic target in remyelination strategies.
References
